TCT Late-Breaker: Point-Of-Care Genetic Test Guides Antiplatelet Therapy
This article was originally published in The Gray Sheet
Data presented at TCT may support rapid, point-of-care genetic testing in tailoring antiplatelet therapy, but clinicians are still not convinced.
You may also be interested in...
Study results on ICD programming, biventricular pacing and more from the 2012 AHA Scientific Sessions in Los Angeles.
A recent study supports a role for genetic testing as a means of personalizing antiplatelet therapy following stent placement and builds the case that newer drugs, such as Eli Lilly/Daiichi Sankyo's Effient (prasugrel), are more appropriate options for those who have poor response to standard Plavix (clopidogrel) treatment.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.